The tachycardia-bradycardia syndrome.
The tachycardia-bradycardia syndrome (paroxysmal atrial fibrillation, flutter, or tachycardia followed by sinoatrial block or sinus arrest resulting in Stokes-Adams attacks) is an important clinical entity that requires familiarity by the clinician. Pathologic studies and physiologic mechanisms as revealed in the electrocardiogram indicate multiple disturbances in the conduction system of the heart (sinus node, atria, and atrioventricular junctional tissues). The electrocardiogram establishes the diagnosis. Pacemaker implantation with supplementary drugs has provided a satisfactory means of therapy. With proper treatment the prognosis of patients with the tachycardia-bradycardia syndrome has improved to the extent that the primary determinant of mortality is no longer the arrhythmia, but the underlying cardiac and/or systemic pathology.
D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000150:complications / Q000473:pathology; D001283:Atrioventricular Node / Q000473:pathology / Q000503:physiopathology; D001919:Bradycardia / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D004562:Electrocardiography; D006325:Heart Atria / Q000473:pathology; D006329:Heart Conduction System / Q000503:physiopathology; D006349:Heart Valve Diseases / Q000209:etiology; D006801:Humans; D010138:Pacemaker, Artificial; D011379:Prognosis; D013577:Syndrome; D013610:Tachycardia / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy
D000889:Anti-Arrhythmia Agents